Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00792142
Recruitment Status : Active, not recruiting
First Posted : November 17, 2008
Last Update Posted : February 12, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2019
  Estimated Study Completion Date : April 2019